CN102838534A - Preparation method of flupirtine maleate - Google Patents
Preparation method of flupirtine maleate Download PDFInfo
- Publication number
- CN102838534A CN102838534A CN2012103817053A CN201210381705A CN102838534A CN 102838534 A CN102838534 A CN 102838534A CN 2012103817053 A CN2012103817053 A CN 2012103817053A CN 201210381705 A CN201210381705 A CN 201210381705A CN 102838534 A CN102838534 A CN 102838534A
- Authority
- CN
- China
- Prior art keywords
- midbody
- reaction vessel
- toxilic acid
- stirring
- ethyl alcohol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention provides a novel preparation method of flupirtine maleate; the method mainly comprises steps of substitution reaction, reduction reaction, acylation reaction, salt forming reaction and refining. It is proved by small and medium scale tests that a novel process route and reaction process are achievable, technical parameters are stable, reproducibility is good and product quality is stable.
Description
Technical field
The invention belongs to the chemicals preparing technical field.Particularly, the present invention relates to the preparation method of toxilic acid flupirtine.
Background technology
The toxilic acid flupirtine is a kind of nonopioid analgesic that acts on cns; It is a kind of selectivity neuron potassium channel openers (Selective Neuronal Potassium Channel Opener; SNEPCO), have pain relieving, of flaccid muscles and neuroprotective three efficacy.Be mainly used in the treatment of various types of moderate acute pains, the pain and headache/migraine and the abdominal cramps etc. that cause like surgical operation, wound etc.
The English name of toxilic acid flupirtine is: Flupirtine Maleate, chemical name: 2-amino-6-[((4-fluorophenyl) methyl) amino] pyridine-3-urethanum PHENRAMINE MALEATE; Chemical abstracts (CAS) number: 75507-68-5; Molecular formula: C
15H
17FN
4O
2C
4H
4O
4Molecular weight: 420.39; Its structural formula is:
See that from structure the toxilic acid flupirtine is the molecule-type compound, by the verivate and the synthetic flupirtine that makes of pyridine derivate of benzene, flupirtine forms organic salt with toxilic acid again.Comprehensive relevant document, the synthetic route of toxilic acid flupirtine mainly contains two, and is existing that its main synthesis step division is following.
Route 1 (WO 98/47872A1): this route is with 2, and 6-two chloro-3-nitropyridines are raw material, through replacement, ammonification, high-pressure hydrogenation, acidylate, salify, process such as refining.Reaction formula is following:
。
Route 2 (US5959115A) is a starting raw material with 2-amino-3-nitro-6-methoxypyridine; Warp and NSC 158269 generation substitution reaction generate 2-amino-3-nitro-6-NSC 158269 yl pyridines, and yield is 95.2%; High-pressure hydrogenation reduction then; Filtration catalizer gets the flupirtine hydrochloride with Vinyl chloroformate generation acylation reaction again, and three step total recoverys are 53.3%.Reaction formula is following:
。
Route 1,2 starting raw materials are different, but comparatively speaking, route 1 easy control of reaction conditions, and 2-amino-3-nitro 6-chloropyridine is a kind of common chemical raw materials, buys easily on the market, can shorten reaction scheme like this.Route 2 three-step reactions, operational path is short, but raw material 2-amino-3-nitro-6-methoxypyridine expensive, hydrogenation, two step of acidylate yield have only 56.0%.
All disclose the preparation method of toxilic acid flupirtine among one Chinese patent application publication No. CN102241626A and the CN102260209A, but the preparation method in these two parts of applications is a laboratory scale, is not optimized to large-scale industrialization production.
In the present invention; The basis that our selected above-mentioned route 1 is developed for synthetic route is through the substitutability analysis of reacting phase system, chemical unit design, raw material and reagent, particularly through lab scale and pilot plant test; Proved that new operational path and reaction process are practical; Processing parameter is stable, favorable reproducibility, product with stable quality.
Summary of the invention
The preparation method of toxilic acid flupirtine of the present invention mainly comprises following five steps reaction.
The first step: substitution reaction
Main technologic parameters: 1, about 80 ℃ of temperature (80 ℃ ± 5 ℃), 2-amino-3-nitro-6-chloropyridine and NSC 158269 molar ratio 1.0:1.2; 2, about 4 hours (4 ± 0.5 hours) of backflow; 3, (60 ℃ ± 5 ℃) about vacuum-drying 6-8 hour about 60 ℃.
Second step: reduction reaction
Main technologic parameters: 1, about 80 ℃ of temperature (80 ℃ ± 5 ℃).
The 3rd step: acylation reaction
Main technologic parameters: 1, F1 and Vinyl chloroformate molar ratio 1.0:1.15-1.5; 2, temperature control is no more than 50 ℃, drips Vinyl chloroformate; 3, normal temperature drips the triethylamine neutralization.
The 4th step: salt-forming reaction
Main technologic parameters: 1,60 ℃ ± 5 ℃ following salifies; 2, water as solvent.
The 5th step: refining:
Main technologic parameters: in absolute ethyl alcohol, 65 ℃ ± 5 ℃ stirring and dissolving post crystallizations.
The chemical substance relevant information that relates in each step is as follows:
Midbody F1:2-amino-3-nitro-6-NSC 158269 yl pyridines;
Midbody F2:2,3-diamino--6-NSC 158269 yl pyridines;
Midbody F3: flupirtine.
Their chemical formula is respectively:
In one embodiment, the invention provides a kind of preparation method of toxilic acid flupirtine, may further comprise the steps:
(1) 2-amino-3-nitro-6-chloropyridine, yellow soda ash, absolute ethyl alcohol, pyridine and NSC 158269 80 ℃ ± 5 ℃ back flow reaction in first reaction vessel obtain midbody F1;
(2) midbody F1, absolute ethyl alcohol, Raney's nickel and Hydrazine Hydrate 80 80 ℃ ± 5 ℃ back flow reaction in second reaction vessel are reacted the after-filtration that finishes, and filtrating moves in the 3rd reaction vessel and removes solvent under reduced pressure to there not being distillate, obtains the midbody F2 of solid-like;
(3) absolute ethyl alcohol is added in said the 3rd reaction vessel, drip Vinyl chloroformate, temperature must not surpass 50 ℃ in the dropping process, drips triethylamine then, transfers pH to 7～8, removes solvent under reduced pressure to there not being distillate, gets the midbody F3 of solid-like; With
(4) purified water is added in said the 3rd reaction vessel, is warming up to 60 ℃ ± 5 ℃ dissolving midbody F3 under stirring, then the toxilic acid aqueous solution is joined in said the 3rd reaction vessel; Continue to stir, be cooled to the room temperature crystallization afterwards, filter; Collect filter cake, obtain toxilic acid flupirtine bullion.
In further embodiment, the preparation method of said toxilic acid flupirtine further comprises step:
(5) toxilic acid flupirtine bullion 65 ℃ ± 5 ℃ stirring and dissolving post crystallizations in absolute ethyl alcohol.
In further embodiment, said step (1) is:
2-amino-3-nitro-6-chloropyridine, yellow soda ash, absolute ethyl alcohol, pyridine are dropped in first reaction vessel, be heated with stirring to 80 ℃ ± 5 ℃, occur obviously refluxing; NSC 158269 slowly is added drop-wise in the reaction vessel,, stops heating 80 ℃ ± 5 ℃ stirring and refluxing reactions 4 ± 0.5 hours; Add purified water, be cooled to normal temperature (25 ℃ ± 5 ℃) under stirring, separate out yellow crystal; Filter, collect filter cake, with purified water washing leaching cake 2 times; 60 ℃ ± 5 ℃ vacuum-drying 6-8 hour, obtain midbody F1.
In further embodiment, said step (2) is:
Midbody F1, absolute ethyl alcohol and Raney's nickel are joined in second reaction vessel; Be heated with stirring to 80 ℃ ± 5 ℃; Drip Hydrazine Hydrate 80 after occurring refluxing, dropwise the back and stirred 1 ± 0.5 hour, filter; To filtrate to move in the 3rd reaction vessel removes solvent under reduced pressure to there not being distillate, obtains the midbody F2 of solid-like.
In further embodiment, said step (3) is:
Absolute ethyl alcohol is added in said the 3rd reaction vessel; Stir down and drip Vinyl chloroformate, temperature must not surpass 50 ℃ in the dropping process, drips off continued and stirs 2 ± 0.5 hours; Drip triethylamine then; Transfer pH to 7～8, stir and remove solvent after 30 ± 5 minutes under reduced pressure, get the midbody F3 of solid-like to there not being distillate.
In further embodiment, said step (4) is:
Purified water is added in said the 3rd reaction vessel, is warming up to 60 ℃ ± 5 ℃ dissolving midbody F3 under stirring, then the toxilic acid aqueous solution is joined in said the 3rd reaction vessel; Have solids to separate out, 60 ℃ ± 5 ℃ are continued down to stir 1 ± 0.5 hour, are cooled to room temperature and continued stirring and crystallizing 5-10 hour; Filter, with purified water washing, absolute ethanol washing; Collect filter cake, obtain toxilic acid flupirtine bullion.
In further embodiment, said step (5) is:
In the 4th reaction vessel, add absolute ethyl alcohol, add toxilic acid flupirtine bullion again, be heated to 65 ℃ ± 5 ℃ under stirring and dissolve to solid; Add gac, insulated and stirred 15-30 minute, heat filtered gac, and filtrating gets in the crystallizer after smart filter; Stir down and be cooled to stirring at room 1 hour, separate out floss after, be cooled to 0 ℃ ± 5 ℃, continuation stirring and crystallizing 5-10 hour; Filter, collect filter cake, behind the absolute ethanol washing filter cake with filter cake 60 ℃ ± 5 ℃ vacuum-drying 6-8 hour.
In further embodiment, the mol ratio of 2-amino in said step (1)-3-nitro-6-chloropyridine and NSC 158269 is 1.0:1.2-1.5, and is preferred, 1.0:1.2.
In further embodiment, in said step (2), the amount of the midbody F1 that uses according to step (2), the mol ratio of midbody F1 and Hydrazine Hydrate 80 is 1:4-8, preferably, and 1:4-6, preferred, 1:4-5.
In further embodiment, in said step (3), the amount of the midbody F1 that uses according to step (2), the mol ratio of midbody F1 and Vinyl chloroformate is 1:1.15-1.5.
In further embodiment, in said step (4), the amount of the midbody F1 that uses according to step (2), the mol ratio of midbody F1 and toxilic acid is 1:1.0-1.5.
In one embodiment, the invention provides a kind of preparation method of toxilic acid flupirtine, may further comprise the steps:
(1) 2-amino-3-nitro-6-chloropyridine, yellow soda ash, absolute ethyl alcohol, pyridine are dropped in first reaction vessel, be heated with stirring to 80 ℃ ± 5 ℃, occur obviously refluxing, slowly be added drop-wise to NSC 158269 in the reaction vessel; 80 ℃ ± 5 ℃ stirring and refluxing reactions 4 ± 0.5 hours, stop heating, add purified water, be cooled to normal temperature under stirring; Separate out yellow crystal, filter, collect filter cake; With purified water washing leaching cake 2 times, 60 ℃ ± 5 ℃ vacuum-drying 6-8 hour, obtain midbody F1;
(2) midbody F1, absolute ethyl alcohol and Raney's nickel are joined in second reaction vessel; Be heated with stirring to 80 ℃ ± 5 ℃; Drip Hydrazine Hydrate 80 after occurring refluxing, dropwise the back and stirred 1 ± 0.5 hour, filter; To filtrate to move in the 3rd reaction vessel removes solvent under reduced pressure to there not being distillate, obtains the midbody F2 of solid-like;
(3) absolute ethyl alcohol is added in said the 3rd reaction vessel; Stir down and drip Vinyl chloroformate, temperature must not surpass 50 ℃ in the dropping process, drips off continued and stirs 2 ± 0.5 hours; Drip triethylamine then; Transfer pH to 7～8, stir and remove solvent after 30 ± 5 minutes under reduced pressure, get the midbody F3 of solid-like to there not being distillate;
(4) purified water is added in said the 3rd reaction vessel, is warming up to 60 ℃ ± 5 ℃ dissolving midbody F3 under stirring, then the toxilic acid aqueous solution is joined in said the 3rd reaction vessel; Have solids to separate out, 60 ℃ ± 5 ℃ are continued down to stir 1 ± 0.5 hour, are cooled to room temperature and continued stirring and crystallizing 5-10 hour; Filter, with purified water washing, absolute ethanol washing; Collect filter cake, obtain toxilic acid flupirtine bullion; With
(5) in the 4th reaction vessel, add absolute ethyl alcohol, add toxilic acid flupirtine bullion again; Be heated to 65 ℃ ± 5 ℃ under stirring to the solid dissolving, add gac, insulated and stirred 15-30 minute; Heat filters gac, and filtrating gets in the crystallizer after smart filter, is cooled to stirring at room 1 hour under stirring; After separating out floss, be cooled to 0 ℃ ± 5 ℃, continued stirring and crystallizing 5-10 hour; Filter, collect filter cake, behind the absolute ethanol washing filter cake with filter cake 60 ℃ ± 5 ℃ vacuum-drying 6-8 hour.
Detailed description of the invention
One, operational path confirms
So the selected described route 1 of preamble is a synthetic route, and changes hydrogenation reduction process, uses safer and more effective Hydrazine Hydrate 80 to be reductive agent, this has shortened the reaction times greatly.Study on the synthesis route reaction formula is following:
In the synthesis technique of confirming, be raw material with 2-amino-3-nitro-6-chloropyridine, through replacement, reduction, acidylate, salify, flupirtine such as refining.The reaction that technology relates to mainly is a not homogeneous reaction of solid-liquid, and the raw material and the reagent of use have substitutability, and main chemical process flow has solid-separation, solid-liquid separation etc. Gu make the toxilic acid unit operation.To above characteristics, several kinds of factors below when process design, mainly considering.
(1) is directed against not homogeneous reaction
In synthesis technique; Midbody 2-amino-3-nitro-6-NSC 158269 yl pyridines (F1); 2,3-diamino--6-NSC 158269 yl pyridines (F2), flupirtine (F3) and the finished product toxilic acid flupirtine synthetic; Be not homogeneous reaction, when reactor design, taken into full account the state of the art of present chemical plant.
Midbody F1, F2's is synthetic, and reaction conditions is similar, requires to have backflow; Consider the synthetic continuity; We carry out synthetic, the neutralization reaction of midbody F3 in concentrating in the same reactor drum, this not only effectively solves flupirtine alkali and is prone to oxidized problem, and can save into alkali, neutral conversion unit; The HCl that has sharp aroma, the organic amine that particularly generate can better be dissolved in the mother liquor; Can reclaim then, operator's Working environment is improved, also reduce fixing
The input of assets.
When selective reaction medium, solvent, that emphasis uses is nontoxic, cheap, steady quality, the organism that can recycle.Midbody F1's is synthetic, and methyl alcohol, ethanol, Virahol etc. are according with process requirements all, but final safety non-toxic, the cheap ethanol selected; In the preparation of A crystal formation, also select ethanol to make solvent, mother liquor recycles after reclaiming.
(2) to the substitutability of raw material and reagent
As previously mentioned, except that solvent, medium, in the selection of raw material and reagent, also follow this thinking.In the alkali reagent that uses, caustic soda, Ke Xingjia, soda ash, triethylamine, diethylamine all can, except that irreplaceable, select the most cheap chemicals soda ash in the technology as far as possible, this not only reduces synthetic cost, more environmental protection eases off the pressure; In toxilic acid flupirtine synthetic; Make water, ethanol, methyl alcohol, Virahol all passable, but consider the synthetic cost, select water to make solvent at last; Not only reduce production costs greatly; But also find to remove the strong impurity of segment polarity in the technology, reach the ideal technology requirement, reduce the pressure of environmental protection.
The selection of reagent sees the following form
。
(3) chemical unit design
In the chemical unit that relates to, solid-liquid inhomogeneous reaction, solid-liquid separate and occupy main proportion, so when design, emphasis is considered the chemical plant of existing moulding, promptly mainly consider the chemical plant of GB standard.Main reaction kettle, separating device can reach processing requirement at present.
(4) product crystal formation research
According to relevant bibliographical information, the toxilic acid flupirtine has three kinds of crystal formations--and-A, B, S type, wherein the S type is called the solvent crystal formation again, because the A crystal formation has characteristics such as solubleness is good, bioavailability is high, finished product is stable, so require finished product A crystal formation content high.
In crystal formation research, we adopt different solvents such as absolute ethyl alcohol, methyl alcohol, sherwood oil, ETHYLE ACETATE, Virahol respectively, on processing condition respectively with temperature, whether stir be parameter.Experimental result shows, at sherwood oil, ETHYLE ACETATE because solubleness is little, so do not adopt this two solvents; Absolute ethyl alcohol, methyl alcohol, Virahol all can reach the crystal formation content requirement under various conditions; In all solvents, all need to stir.
Finally confirm with ethanol to be solvent, temperature is 65 ℃ ± 5 ℃ a crystal formation preparation condition.Following table has shown the result of crystal formation preparation condition research.
√ contains qualified A crystal formation; * A crystal formation content is defective.
In order to study different crystal forms character better,, find out the preparation method of pure A, B crystal formation also through the conversion crystallization condition.
Two, technical study is summed up
Through the substitutability analysis of reacting phase system, chemical unit design, raw material and reagent, particularly, proved that operational path and reaction process are practical through lab scale and pilot plant test, processing parameter is stable, favorable reproducibility, product with stable quality.
The important technical parameter result of study sees the following form:
Embodiment 1---the preparation experiment of toxilic acid flupirtine
(1) substitution reaction----midbody F1's is synthetic
I, charging capacity and proportioning
| Title | Kg | mol |
| 2-amino-3-nitro-6-chloropyridine | 5.0 | 28.9 |
| Absolute ethyl alcohol | 14.0 | -- |
| NSC 158269 | 4.3 | 34.4 |
| Yellow soda ash | 6.02 | -- |
| Pyridine | 0.85 | -- |
| Purified water | 34.0 | -- |
II, experimentation
2-amino-3-nitro-6-chloropyridine, yellow soda ash, absolute ethyl alcohol, pyridine are put in the exsiccant 211# reaction kettle, opened and stir and be heated to (80 ℃ ± 5 ℃) about 80 ℃, occur obviously refluxing; NSC 158269 slowly is added drop-wise in the reaction kettle, and after dropwising, (80 ℃ ± 5 ℃) stirring and refluxing was reacted about 4 hours about 80 ℃.
Stop heating, add the 34.0kg purified water, be cooled to normal temperature (25 ℃ ± 5 ℃) under stirring, have a large amount of yellow crystals to separate out.
Filter, collect filter cake, with an amount of purified water washing leaching cake 2 times, 60 ℃ vacuum-drying 6-8 hour.
Product: 6.8kg.
Yield scope: 85.0-95.0%.
III, midbody control
Outward appearance: middle this F1 is a yellow powder shape solid;
HPLC measures midbody F1 content>=95%, NSC 158269 limit≤0.5%.(normalization method).
(2) reduction reaction----midbody F2's is synthetic
I, charging capacity and proportioning
| Title | Kg | mol |
| Midbody F1 | 6.8 | 26 |
| 80% Hydrazine Hydrate 80 | 5.4 | 108 |
| Absolute ethyl alcohol | 51.0 | -- |
| Raney's nickel | 580.0g | -- |
II, operating process
The Raney's nickel of midbody F1, absolute ethyl alcohol and catalytic amount is joined in the 201# reaction kettle, open and stir, be warming up to (80 ℃ ± 5 ℃) about 80 ℃, drip Hydrazine Hydrate 80 (according to response situation, consumption is at 5.4-10.5kg) as early as possible after occurring refluxing.Stirred 1 ± 0.5 hour after dropwising, filter, will filtrate to move into removes solvent under reduced pressure to there not being distillate in the 210# reaction kettle, get the solid-like thing, after the TLC detection is errorless, drops into next step reaction.
III, midbody control
TLC detects: ETHYLE ACETATE: after launching in the developping agent of sherwood oil ≈ 1:1, and colour developing under ultraviolet 254nm.
Rf ≈ 0.6 is a target compound.
(3) acylation reaction----midbody F3's is synthetic
I, charging capacity and proportioning
| Title | Kg | mol |
| Midbody F2 | -- | -- |
| Vinyl chloroformate | 4.25 | 39.35 |
| Absolute ethyl alcohol | 38.0 | -- |
| Triethylamine | 3.1 | 30.7 |
II, operating process
Absolute ethyl alcohol 38kg is added in the 210# reaction kettle, stirs down and drip Vinyl chloroformate 4.25kg (according to response situation, consumption is at 3.25-4.25kg), temperature must not surpass 50 ℃ in the dropping process, drips off continued and stirs 2 hours.Drip triethylamine 3.1kg (actual amount is as the criterion with pH) then, transfer pH to 7～8, stir and remove solvent under reduced pressure to there not being distillate after 30 minutes.Get the solid-like thing, TLC detects errorless back and drops into next step reaction.
III, quality control
TLC detects
ETHYLE ACETATE: sherwood oil ≈ 4:1.
Rf ≈ 0.7 is a target compound.
(4) synthesizing of salt-forming reaction----toxilic acid flupirtine
I, charging capacity and proportioning
| Title | Kg | mol |
| Toxilic acid | 3.1 | 26.7 |
| Purified water | 120.0 | -- |
II, operating process
The 120.0kg purified water is added in the 210# reaction kettle, is warming up to 60 ℃ ± 5 ℃ under stirring; Other gets the 3.1kg toxilic acid and is dissolved in the 17kg purified water; Then the toxilic acid aqueous solution is joined in the 210# reaction kettle, have a large amount of solidss to separate out, 60 ℃ ± 5 ℃ are continued to stir 1h down; Be cooled to room temperature and continued stirring and crystallizing 5-10 hour, filter, wash with purified water; Absolute ethanol washing is collected filter cake, gets into next step rectification flow.
III, quality control
TLC detects: ETHYLE ACETATE: sherwood oil ≈ 4:1.Rf ≈ 0.7 is a target compound.
(5) preparation of refining----crystal form A
I, charging capacity and proportioning
| Title | Kg | mol |
| Absolute ethyl alcohol | 120.0 | -- |
| Toxilic acid | 0.17 | 1.47 |
| Gac | 0.68 | -- |
II, experimentation
In the 300L reaction kettle, add absolute ethyl alcohol 120kg, add the toxilic acid of toxilic acid flupirtine bullion and 170g again; Be heated to 65 ℃ ± 5 ℃ under stirring to the solid dissolving, add the 680.0g gac, insulated and stirred 15-30 minute; Heat filters gac, and filtrating gets in the clean area 500L crystallizer after smart filter, is cooled to stirring at room 1 hour under stirring; After separating out a large amount of flosss, be cooled to (0 ℃ ± 5 ℃) about 0 ℃, continued stirring and crystallizing 5-10 hour; Filter, collect filter cake, behind the absolute ethanol washing filter cake with about 60 ℃ of filter cakes (60 ℃ ± 5 ℃) vacuum-drying 6-8 hour.
Filter cake was pulverized the whole grain of 40 mesh sieves, weighing products packing warehouse-in.
III, quality control
Outward appearance: white crystal.
Fusing point: 172-176 ℃.
Embodiment 2---the control of committed step and making with extra care of product
The production of these article is divided into substitution reaction, reduction reaction, acylation reaction; Salify, in refining five steps, wherein substitution reaction can obtain solid product; The product of reduction reaction and acylation reaction is difficult for making solid in operation; And product is prone to oxidation, and it is refining that the bullion that salify makes is difficult for the later stage after because of drying, and a spot of water that contains in the bullion is to the not significantly influence of quality of finished product.In experimentation, our emphasis is temperature of reaction, the material feed ratio, and the reaction times is progressively found out relevant parameters as research object.
In synthesis technique, the product of substitution reaction is midbody F1 and can be separated preferably, and midbody F1 is the basic framework that forms the finished product toxilic acid flupirtine, and the quality of its quality not only influences the second step three step process.So F1 is confirmed as key intermediate and quality detection in addition.
When needed, midbody F1 is made with extra care.The process for purification of midbody F1 is following:
The process for purification of toxilic acid flupirtine the finished product is following:
Under 65 ℃ ± 5 ℃ toxilic acid flupirtine bullion is mixed with mass ratio 1:30-40 with absolute ethyl alcohol, bullion dissolves fully, adds the 680g gac again; Stirred 15-30 minute, filtered while hot is got filtrating; Stirring drops to room temperature; Be chilled to 0 ℃ of crystallization 5-10 hour again, cross the leaching filter cake, the filter cake oven dry is got final product.
Embodiment 3---and multiple batches of technical study and data thereof gather
Carried out a plurality of batches, the trial-production of different batch weights according to the described toxilic acid flupirtine of preamble preparation method, yield and quality product are studied, data are as shown in the table.Data show that compound method of the present invention is reliable and stable, can obtain highly purified product, and related substances is very low with maximum single assorted content simultaneously, and processing parameter is stable, favorable reproducibility, product with stable quality.
Claims (12)
1. the preparation method of a toxilic acid flupirtine may further comprise the steps:
(1) 2-amino-3-nitro-6-chloropyridine, yellow soda ash, absolute ethyl alcohol, pyridine and NSC 158269 80 ℃ ± 5 ℃ back flow reaction in first reaction vessel obtain midbody F1;
(2) midbody F1, absolute ethyl alcohol, Raney's nickel and Hydrazine Hydrate 80 80 ℃ ± 5 ℃ back flow reaction in second reaction vessel are reacted the after-filtration that finishes, and filtrating moves in the 3rd reaction vessel and removes solvent under reduced pressure to there not being distillate, obtains the midbody F2 of solid-like;
(3) absolute ethyl alcohol is added in said the 3rd reaction vessel, drip Vinyl chloroformate, temperature must not surpass 50 ℃ in the dropping process, drips triethylamine then, transfers pH to 7～8, removes solvent under reduced pressure to there not being distillate, gets the midbody F3 of solid-like; With
(4) purified water is added in said the 3rd reaction vessel, is warming up to 60 ℃ ± 5 ℃ dissolving midbody F3 under stirring, then the toxilic acid aqueous solution is joined in said the 3rd reaction vessel; Continue to stir, be cooled to the room temperature crystallization afterwards, filter; Collect filter cake, obtain toxilic acid flupirtine bullion.
2. according to the method for claim 1, further comprise step:
(5) toxilic acid flupirtine bullion 65 ℃ ± 5 ℃ stirring and dissolving post crystallizations in absolute ethyl alcohol.
3. according to the process of claim 1 wherein that said step (1) is:
2-amino-3-nitro-6-chloropyridine, yellow soda ash, absolute ethyl alcohol, pyridine are dropped in first reaction vessel, be heated with stirring to 80 ℃ ± 5 ℃, occur obviously refluxing, slowly be added drop-wise to NSC 158269 in the reaction vessel; 80 ℃ ± 5 ℃ stirring and refluxing reactions 4 ± 0.5 hours, stop heating, add purified water, be cooled to normal temperature under stirring; Separate out yellow crystal, filter, collect filter cake; With purified water washing leaching cake 2 times, 60 ℃ ± 5 ℃ vacuum-drying 6-8 hour, obtain midbody F1.
4. according to the process of claim 1 wherein that said step (2) is:
Midbody F1, absolute ethyl alcohol and Raney's nickel are joined in second reaction vessel; Be heated with stirring to 80 ℃ ± 5 ℃; Drip Hydrazine Hydrate 80 after occurring refluxing, dropwise the back and stirred 1 ± 0.5 hour, filter; To filtrate to move in the 3rd reaction vessel removes solvent under reduced pressure to there not being distillate, obtains the midbody F2 of solid-like.
5. according to the process of claim 1 wherein that said step (3) is:
Absolute ethyl alcohol is added in said the 3rd reaction vessel; Stir down and drip Vinyl chloroformate, temperature must not surpass 50 ℃ in the dropping process, drips off continued and stirs 2 ± 0.5 hours; Drip triethylamine then; Transfer pH to 7～8, stir and remove solvent after 30 ± 5 minutes under reduced pressure, get the midbody F3 of solid-like to there not being distillate.
6. according to the process of claim 1 wherein that said step (4) is:
Purified water is added in said the 3rd reaction vessel, is warming up to 60 ℃ ± 5 ℃ dissolving midbody F3 under stirring, then the toxilic acid aqueous solution is joined in said the 3rd reaction vessel; Have solids to separate out, 60 ℃ ± 5 ℃ are continued down to stir 1 ± 0.5 hour, are cooled to room temperature and continued stirring and crystallizing 5-10 hour; Filter, with purified water washing, absolute ethanol washing; Collect filter cake, obtain toxilic acid flupirtine bullion.
7. according to the method for claim 2, wherein said step (5) is:
In the 4th reaction vessel, add absolute ethyl alcohol, add toxilic acid flupirtine bullion again, be heated to 65 ℃ ± 5 ℃ under stirring and dissolve to solid; Add gac, insulated and stirred 15-30 minute, heat filtered gac, and filtrating gets in the crystallizer after smart filter; Stir down and be cooled to stirring at room 1 hour, separate out floss after, be cooled to 0 ℃ ± 5 ℃, continuation stirring and crystallizing 5-10 hour; Filter, collect filter cake, behind the absolute ethanol washing filter cake with filter cake 60 ℃ ± 5 ℃ vacuum-drying 6-8 hour.
8. according to the method for claim 1, the mol ratio of 2-amino in said step (1)-3-nitro-6-chloropyridine and NSC 158269 is 1.0:1.2-1.5, and is preferred, 1.0:1.2.
9. according to the method for claim 1, in said step (2), the amount of the midbody F1 that uses according to step (2), the mol ratio of midbody F1 and Hydrazine Hydrate 80 is 1:4-8, preferably, and 1:4-6, preferred, 1:4-5.
10. according to the method for claim 1, in said step (3), the amount of the midbody F1 that uses according to step (2), the mol ratio of midbody F1 and Vinyl chloroformate is 1:1.15-1.5.
11. according to the method for claim 1, in said step (4), the amount of the midbody F1 that uses according to step (2), the mol ratio of midbody F1 and toxilic acid is 1:1.0-1.5.
12. each the toxilic acid flupirtine of method preparation according to claim 1-11.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012103817053A CN102838534A (en) | 2012-10-10 | 2012-10-10 | Preparation method of flupirtine maleate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012103817053A CN102838534A (en) | 2012-10-10 | 2012-10-10 | Preparation method of flupirtine maleate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102838534A true CN102838534A (en) | 2012-12-26 |
Family
ID=47366295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012103817053A Pending CN102838534A (en) | 2012-10-10 | 2012-10-10 | Preparation method of flupirtine maleate |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102838534A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103086963A (en) * | 2013-01-29 | 2013-05-08 | 吉林修正药业新药开发有限公司 | Synthetic method of flupirtine maleate A-type crystal compound and midbody |
| CN103333103A (en) * | 2013-07-12 | 2013-10-02 | 南京正大天晴制药有限公司 | Method for preparing flupirtine maleate by one-pot method |
| CN104817494A (en) * | 2015-04-22 | 2015-08-05 | 江苏海岸药业有限公司 | Method for synthesizing flupirtine maleate by use of one-pot process |
| CN106397313A (en) * | 2016-08-31 | 2017-02-15 | 安徽省润生医药股份有限公司 | High efficient synthesis method of flupirtine maleate |
| CN109053563A (en) * | 2018-07-20 | 2018-12-21 | 四川青木制药有限公司 | A method of preparing hydrochloric acid Flupirtine |
| CN109053562A (en) * | 2018-07-20 | 2018-12-21 | 四川青木制药有限公司 | A method of preparing the flupirtine maleate of the high heap density of A crystal form |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010136113A1 (en) * | 2009-05-29 | 2010-12-02 | Corden Pharmachem Gmbh | Method for producing flupirtine |
| CN102241626A (en) * | 2011-05-03 | 2011-11-16 | 北京华睿鼎信科技有限公司 | Synthesis process of flupirtine maleate |
-
2012
- 2012-10-10 CN CN2012103817053A patent/CN102838534A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010136113A1 (en) * | 2009-05-29 | 2010-12-02 | Corden Pharmachem Gmbh | Method for producing flupirtine |
| CN102241626A (en) * | 2011-05-03 | 2011-11-16 | 北京华睿鼎信科技有限公司 | Synthesis process of flupirtine maleate |
Non-Patent Citations (2)
| Title |
|---|
| YONG M. CHOI ET AL.: "A NINE-STEP SYNTHESIS OF [14C]FLUPIRTINE MALEATE LABELED IN THE PYRIDINE RING", 《JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICA》 * |
| 郭玉莹: "氟吡汀及其衍生物合成及工艺优化的研究", 《中国优秀硕士学位论文全文数据库 工程科技Ⅰ辑》 * |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103086963A (en) * | 2013-01-29 | 2013-05-08 | 吉林修正药业新药开发有限公司 | Synthetic method of flupirtine maleate A-type crystal compound and midbody |
| CN103333103A (en) * | 2013-07-12 | 2013-10-02 | 南京正大天晴制药有限公司 | Method for preparing flupirtine maleate by one-pot method |
| CN103333103B (en) * | 2013-07-12 | 2015-07-22 | 南京正大天晴制药有限公司 | Method for preparing flupirtine maleate by one-pot method |
| CN104817494A (en) * | 2015-04-22 | 2015-08-05 | 江苏海岸药业有限公司 | Method for synthesizing flupirtine maleate by use of one-pot process |
| CN104817494B (en) * | 2015-04-22 | 2017-09-29 | 江苏海岸药业有限公司 | A kind of method of one pot process flupirtine maleate |
| CN106397313A (en) * | 2016-08-31 | 2017-02-15 | 安徽省润生医药股份有限公司 | High efficient synthesis method of flupirtine maleate |
| CN109053563A (en) * | 2018-07-20 | 2018-12-21 | 四川青木制药有限公司 | A method of preparing hydrochloric acid Flupirtine |
| CN109053562A (en) * | 2018-07-20 | 2018-12-21 | 四川青木制药有限公司 | A method of preparing the flupirtine maleate of the high heap density of A crystal form |
| CN109053563B (en) * | 2018-07-20 | 2022-03-29 | 四川青木制药有限公司 | Method for preparing flupirtine hydrochloride |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102838534A (en) | Preparation method of flupirtine maleate | |
| CN108727334A (en) | A kind of production technology of dabigatran etexilate methanesulfonate | |
| CN104926790A (en) | High-purity Vonoprazan Fumarate compound, intermediate and impurity thereof and preparation methods of high-purity Vonoprazan Fumarate compound, intermediate and impurity | |
| CN103664912B (en) | A kind of synthesis technique of prucalopride | |
| CN104177292A (en) | Method for industrial production of sorafenib tosylate polymorphic form I | |
| CN107200705B (en) | A kind of preparation method of 3- nitro -2- indolone derivatives | |
| CN105669652B (en) | A kind of preparation method of improved benzene sulphur bepotastine | |
| CN103842343A (en) | A crystalline form of the sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzene sulfonamide | |
| CN103813793A (en) | Polymorphic forms of the sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzene sulfonamide | |
| CN107056720A (en) | A kind of preparation and purification method of Valsartan | |
| CN102711764A (en) | Synthesis of a neurostimulative piperazine | |
| CN105669642A (en) | Revaprzan hydrochloride preparation method | |
| CN102367236A (en) | Synthesizing technology of donepezil hydrochloride | |
| CN105218440A (en) | The preparation method of a kind of high-purity Rui Gefeini | |
| CN108610293A (en) | A method of more Weis are prepared using microchannel reaction unit and replace Buddhist nun's intermediate | |
| CN105153169B (en) | A kind of synthetic method of epinastine hydrochloride | |
| CN105461688B (en) | Benzimidazole compound K synthetic method | |
| CN108276414A (en) | A kind of preparation method of citric acid tropsch imatinib | |
| CN101928277B (en) | Preparation method of 4-methyl-3-[[4-(3-pyridyl)-2-pyrimidyl]amino]benzoic acid, related intermediate and application thereof | |
| CN101778824A (en) | Process for producing toluidine compound | |
| CN107698651B (en) | A kind of production technology of high-purity dutasteride | |
| CN102391126A (en) | Method for producing 2, 4-dinitrobenzene methyl ether and 2, 4- dinitrophenol simultaneously | |
| CN105753733A (en) | AHU377 crystal form and preparation method and uses thereof | |
| CN102127081A (en) | Preparation method of adenine | |
| CN103755636A (en) | Method for synthesizing Lorcaserin raceme derivative |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20121226 |